Page last updated: 2024-10-27

fluoxetine and Cryptococcosis

fluoxetine has been researched along with Cryptococcosis in 1 studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Cryptococcosis: Fungal infection caused by genus CRYPTOCOCCUS.

Research Excerpts

ExcerptRelevanceReference
" The present study aimed to validate the efficacy of selective serotonin reuptake inhibitors, fluoxetine hydrochloride (FLH) and paroxetine hydrochloride (PAH), alone and in combination with amphotericin B (AmB) against C."1.62In vitro synergistic effects of fluoxetine and paroxetine in combination with amphotericin B against Cryptococcus neoformans. ( de Menezes, RT; de Oliveira, HC; de Oliveira, LD; Pereira, TC; Scorzoni, L, 2021)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Pereira, TC1
de Menezes, RT1
de Oliveira, HC1
de Oliveira, LD1
Scorzoni, L1

Other Studies

1 other study available for fluoxetine and Cryptococcosis

ArticleYear
In vitro synergistic effects of fluoxetine and paroxetine in combination with amphotericin B against Cryptococcus neoformans.
    Pathogens and disease, 2021, 02-19, Volume: 79, Issue:2

    Topics: Amphotericin B; Antifungal Agents; Biofilms; Cryptococcosis; Cryptococcus neoformans; Drug Synergism

2021